Allison Rosenthal has joined Lykos Therapeutics as the company’s first Chief Commercial Officer. Ms. Rosenthal leads Lykos’ trailblazing commercial strategy and operations, initially focusing on the potential launch of MDMA-assisted therapy for their lead program to treat those suffering with PTSD. If approved by the FDA, anticipated in Q3 of 2024, this will be the first psychedelic-assisted therapy approved for medical use.
Learn more about Allison and her role here.
David Ford has joined Prothena as Chief People Officer. Mr. Ford brings decades of exceptional global biopharma leadership experience to his role at Prothena.
Throughout his career, Mr. Ford has led through significant strategic and challenging operational change with complete understanding and appreciation of what “best” looks like from organizational infrastructure to performance for any specific period of a company’s evolution.
His scope includes commercial expertise on a global scale – through all aspects of portfolio, global commercial build, launch leadership, and full commercial life cycle.
To learn more about Mr. Ford, visit our latest release.
Want to learn more about our Life Science practice?
Contact Beth Ehrgott at behrgott@thealexandergroup.com.
